Spyre Therapeutics, Inc. — Director's Dealing 2016

Apr 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-04-12

Reporting Person: Lowe David George (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-12	Common Stock	C	5658	—	Acquired	5658	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-04-12	Series A Preferred Stock	$0	C	2857	Disposed		Common Stock (2857)	Indirect
2016-04-12	Series B Preferred Stock	$0	C	2801	Disposed		Common Stock (2801)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	206382	Direct

Footnotes

F1: In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.

F2: The Reporting Person serves as a co-trustee.